DavidKeys.com

The American Cancer Society (ACS) has announced significant changes to its prostate cancer screening guidelines, encouraging more men to undergo regular screening and recommending earlier testing for individuals at higher risk. Announced on November 12, 2026, the updated guidelines represent the organization’s first major revision to its prostate cancer screening recommendations since 2010.

The changes reflect growing scientific evidence that regular prostate-specific antigen (PSA) testing can reduce deaths from prostate cancer and help identify potentially dangerous tumors before they spread to other parts of the body.

The new recommendations also address concerns about unnecessary testing, biopsies, and treatments. By incorporating additional diagnostic tools, including MRI scans and biomarker testing, doctors can better determine which patients need further evaluation and which cancers can safely be monitored.

For millions of American men, these updated guidelines could change when they begin prostate cancer screening and how frequently they should be tested.

Why the American Cancer Society Changed Its Prostate Cancer Screening Guidelines

Prostate cancer remains one of the most common cancers affecting men in the United States. It is also the second-leading cause of cancer-related deaths among American men, behind lung cancer.

According to American Cancer Society estimates, approximately 333,830 men will be diagnosed with prostate cancer in 2026, while approximately 36,320 are expected to die from the disease.

For years, prostate cancer screening recommendations have been controversial. Although PSA testing can identify potential cancer early, it can also produce elevated results in men who do not have cancer or identify slow-growing tumors that may never cause serious health problems.

These concerns led to previous recommendations emphasizing discussions between patients and healthcare providers before deciding whether to undergo screening.

However, new research and longer-term studies have strengthened the evidence that PSA-based screening can reduce prostate cancer deaths and advanced-stage diagnoses.

Medical professionals also have better tools for evaluating abnormal PSA results and determining whether immediate treatment is necessary.

The American Cancer Society believes these improvements make regular screening a more effective approach to identifying potentially life-threatening prostate cancers while reducing unnecessary medical procedures.

What Are the New Prostate Cancer Screening Recommendations?

One of the biggest changes is that the American Cancer Society now directly recommends regular PSA-based screening for men in certain age and risk groups.

The recommended screening schedule depends on age, family history, and other risk factors.

1. Men at Average Risk: Begin Screening at Age 50

For men at average risk of developing prostate cancer, the ACS recommends a PSA blood test every two years between the ages of 50 and 69.

This recommendation applies to men who are not Black and do not have a family history of prostate cancer.

Regular testing can help identify changes in PSA levels that may indicate the presence of prostate cancer.

2. Black Men: Begin Screening at Age 45

Black men face a higher risk of developing prostate cancer and are more likely to die from the disease.

For this reason, the American Cancer Society recommends that Black men begin annual PSA screening at age 45 and continue through age 69.

Earlier and more frequent screening is intended to help identify prostate cancer before it reaches an advanced stage.

3. Men With a Family History: Begin Screening at Age 45

Family history is another important risk factor.

The updated guidelines recommend that non-Black men with a strong family history of prostate cancer begin screening at age 45.

Annual screening is recommended for men who have:

• A father, brother, or son diagnosed with prostate cancer before age 65.
• Multiple first-degree relatives diagnosed with prostate cancer at any age.

For men with one first-degree relative diagnosed at age 65 or older, screening every two years is recommended beginning at age 45.

Men with inherited genetic conditions associated with increased prostate cancer risk should also discuss an appropriate screening schedule with their healthcare providers.

4. Men Between Ages 70 and 74: Individualized Screening Decisions

For men between the ages of 70 and 74, the benefits and potential risks of continued screening are less certain.

The ACS recommends that these men discuss their individual circumstances with their healthcare providers.

Factors to consider include:

• Overall health and life expectancy.
• Previous PSA test results.
• Family history.
• Personal preferences.
• Potential risks associated with additional testing and treatment.

Men who decide to continue screening should generally receive a PSA test every two years.

5. Men Age 75 and Older: Screening Generally Not Recommended

The American Cancer Society does not recommend routine prostate cancer screening for men age 75 and older.

The potential benefits of screening generally decrease with age, while the risks of unnecessary testing and treatment increase.

Some exceptionally healthy men between ages 75 and 79 may wish to discuss continued screening with their doctors, particularly if previous PSA results have been rising.

Screening is discouraged after age 80 and is not recommended for men with a life expectancy of less than 10 years, regardless of age.

What Is a PSA Test and Why Is It Important?

The prostate-specific antigen test, commonly known as the PSA test, is the primary screening method recommended by the American Cancer Society.

PSA is a protein produced by cells in the prostate gland. A simple blood test measures the amount of PSA circulating in the bloodstream.

Elevated PSA levels can sometimes indicate prostate cancer, but they do not automatically mean someone has cancer.

Other conditions can also increase PSA levels, including:

• Benign prostatic hyperplasia (BPH), an enlargement of the prostate.
• Prostatitis, or inflammation of the prostate.
• Urinary tract infections.
• Recent medical procedures involving the prostate.

PSA levels can also fluctuate naturally.

Under the updated ACS recommendations, men ages 45 through 69 with PSA levels of 3.0 ng/mL or higher should have the result repeated, preferably within two weeks to three months.

For men ages 70 through 74, the recommended threshold for repeat testing is 6.5 ng/mL or higher.

Confirming an elevated PSA result helps prevent unnecessary medical procedures resulting from a temporary increase.

New Diagnostic Tools Could Reduce Unnecessary Prostate Biopsies

Another important part of the updated guidelines involves what happens after an elevated PSA test.

In the past, an abnormal PSA result could lead relatively quickly to a prostate biopsy. Although biopsies can help identify cancer, they also carry potential complications, including infection, bleeding, and discomfort.

The updated recommendations encourage additional testing before proceeding with a biopsy.

For most men with a confirmed elevated PSA, doctors should offer further evaluation using:

Magnetic Resonance Imaging (MRI)

An MRI scan produces detailed images of the prostate and surrounding tissue. It can help doctors identify suspicious areas and determine whether a biopsy is necessary.

Biomarker Testing

Certain additional blood or urine tests can help estimate the likelihood that a patient has clinically significant prostate cancer.

These tests provide doctors with additional information when deciding whether further investigation is appropriate.

Together, MRI and biomarker testing can help reduce unnecessary biopsies while improving the identification of cancers that require medical attention.

Active Surveillance: Not Every Prostate Cancer Requires Immediate Treatment

One of the most important aspects of the updated guidelines is the emphasis on active surveillance.

Not all prostate cancers grow quickly or become life-threatening. Some tumors develop so slowly that they may never cause significant health problems during a patient’s lifetime.

Historically, a prostate cancer diagnosis often resulted in recommendations for surgery or radiation therapy.

However, these treatments can produce significant side effects, including:

• Urinary incontinence.
• Erectile dysfunction.
• Bowel complications.
• Other long-term quality-of-life concerns.

For men diagnosed with low-risk prostate cancer, the ACS recommends offering active surveillance as the initial management approach.

Active surveillance involves regularly monitoring the cancer through PSA testing, medical examinations, imaging, and additional testing when appropriate.

If the cancer shows signs of becoming more aggressive, doctors can reconsider treatment options.

This approach helps patients avoid unnecessary treatment while maintaining close medical supervision.

Why Early Prostate Cancer Detection Matters

Prostate cancer frequently develops without noticeable symptoms during its early stages.

When symptoms eventually appear, the disease may already have progressed.

Possible symptoms of prostate cancer include:

• Frequent urination, particularly during the night.
• Difficulty starting or stopping urination.
• Weak or interrupted urine flow.
• Blood in the urine or semen.
• Painful urination.
• Persistent pain in the lower back, hips, or pelvis.

However, these symptoms can also be associated with noncancerous prostate conditions.

Men experiencing these symptoms should consult a healthcare professional rather than relying on screening recommendations alone.

Advanced prostate cancer can spread to nearby tissues, lymph nodes, and bones, making treatment more complicated.

The primary goal of early detection is to identify potentially aggressive cancers before they spread and become more difficult to treat.

What Do the New Guidelines Mean for American Men?

The updated recommendations could have a significant impact on prostate cancer prevention and early detection throughout the United States.

One of the most important changes is the recommendation for routine screening among average-risk men between ages 50 and 69.

The guidelines also recognize that certain populations face a greater risk and should begin screening earlier.

Black men and men with a strong family history are specifically identified as groups that may benefit from earlier and more frequent PSA testing.

The updated recommendations also reflect a broader change in how doctors approach prostate cancer.

Instead of moving directly from an abnormal screening result to a biopsy and potentially aggressive treatment, physicians are encouraged to use additional diagnostic tools to determine which patients actually need intervention.

This approach attempts to balance two important objectives: finding dangerous cancers early and avoiding unnecessary medical procedures.

Questions Men Should Ask Their Doctors About Prostate Cancer Screening

With the new guidelines in place, men may want to schedule a conversation with their healthcare providers about their individual risk.

Some important questions include:

1. When should I begin receiving PSA tests?
2. Does my family history increase my risk of prostate cancer?
3. Should I receive annual or biennial screening?
4. What does an elevated PSA result mean?
5. Would an MRI or biomarker test be appropriate if my PSA is elevated?
6. If I am diagnosed with low-risk prostate cancer, am I a candidate for active surveillance?

Understanding personal risk factors and screening options can help men make informed decisions about their health.

Final Thoughts: A Major Change in Prostate Cancer Detection

The American Cancer Society’s November 2026 update represents a significant change in how prostate cancer screening is recommended in the United States.

After more than 16 years without a major guideline revision, the organization now recommends regular PSA testing for average-risk men between ages 50 and 69, earlier screening for higher-risk individuals, and additional diagnostic testing to reduce unnecessary biopsies and treatments.

The emphasis on MRI, biomarker testing, and active surveillance also recognizes that detecting prostate cancer is only part of the challenge. Determining which cancers require treatment is equally important.

For men approaching middle age, those with a family history of prostate cancer, and particularly Black men, understanding these changes could be an important step toward protecting their long-term health.

The most important takeaway is simple: Talk with your healthcare provider about prostate cancer screening, understand your personal risk, and do not wait for symptoms before discussing early detection.